Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Other solid neoplasm 2Endocrine 2Classical hematology 2Myeloid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3978Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 878Neoplasms 633Breast Neoplasms 596Cholangiocarcinoma 525Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 270Ovarian Neoplasms 235Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 191Head and Neck Neoplasms 185Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 162Adenocarcinoma 156Uterine Cervical Neoplasms 153Bile Duct Neoplasms 153

Interventions

pembrolizumab 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pyridoxine-dependent epilepsy × Gastrointestinal × Clear all
NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

Phase 2 Completed
7 enrolled 14 charts
GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡